Ivermectin is an anthelmintic (avermectin) indicated for strongyloidiasis and onchocerciasis, and topically for rosacea and head lice. We supply it to US manufacturers of tablets, cream and lotion.
Data from PubChem (CID 6321424) and FDA’s substance registry
CAS number
70288-86-7
Molecular formula
C48H74O14
Molecular weight
875.1g/mol
FDA UNII
IUPAC name
(1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
InChIKey
AZSNMRSAGSSBNP-XPNPUAGNSA-N
- Appearance
- White to yellowish-white, non-hygroscopic crystalline powder, melting at about 155 °C.
- Solubility
- Insoluble in water, freely soluble in methanol and soluble in 95% ethanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
A fermentation-derived mixture of two components: at least 90% H2B1a, with H2B1b making up the rest. The drawing above shows H2B1a.
On the US market
- Reference product
- StromectolNDA 050742
- Approved ANDAs
- 11 with a marketed product
- Approved forms and strengths
- Tablet 3 mg, 6 mg
- Topical cream 1%
- Topical lotion 0.5%
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com